Gossamer Bio reports Q2 2026 net income of $16.9M; cash $57.0M, NDA submission for seralutinib on track
Gossamer Bio reported Q2 2026 net income of $16.9M and cash, cash equivalents and marketable securities of $57.0M as of June 30, 2026, citing non-operating gains from debt extinguishment. Revenue from collaborators was $9.2M. The company said it plans to submit an NDA for seralutinib in PAH in Sept 2026 and received FDA Pre-NDA Type B minutes. Shareholders approved a convertible note exchange and a potential reverse stock split.
How this was made
The 30-second read
Why it matters
The combination of Q2 financial results, FDA Pre-NDA Type B meeting minutes, and a stated September 2026 NDA submission plan can shift traders’ expectations for regulatory progress. Capital-structure actions (convertible note exchange and reverse split authorization) add volatility and potential dilution concerns.
Market read
Traders get a fresh regulatory-timeline datapoint (Type B minutes and September NDA plan) plus capital-structure updates, which together can drive biotech probability-of-success repricing.
What to watch
The convertible note exchange and potential reverse split can create near-term share-structure overhang and dilution optics, which may offset positive regulatory momentum.
Background
Gossamer Bio is advancing seralutinib for pulmonary arterial hypertension (PAH) and related indications, with prior collaboration history involving Chiesi.
Ticker impact
Gossamer Bio reported Q2 2026 net income and said it remains on track to submit an NDA for seralutinib in PAH in September 2026 after FDA Type B minutes.
Moderately positive bias into NDA-submission milestones, with volatility around financing/capital-structure actions and FDA acceptance risk.
The article discloses multiple primary items: quarterly financials, FDA Pre-NDA Type B minutes supporting timing, and capital-structure changes (convertible note exchange, reverse split authorization). These can re-rate probability of future approval and affect near-term liquidity/overhang.
Market effects
Reacquisition of seralutinib rights and FDA Type B support reinforces the importance of regulatory process milestones for PAH drug developers.
No clear regional market linkage beyond US biotech sentiment.
Limited direct global spillover; seralutinib rights are worldwide but the disclosed catalyst is US FDA process timing.
Counterpoint
The NDA timing is contingent on filing and FDA acceptance, so the stock may already price the calendar while approval probability remains uncertain.
Key entities
- companyGossamer Bio, Inc.
Reported Q2 2026 net income, disclosed cash position, and reiterated September 2026 NDA submission plan for seralutinib after FDA Type B minutes.
- drug_programseralutinib
PAH candidate whose NDA submission timing is supported by FDA Pre-NDA Type B meeting minutes.
- regulatorFDA
Provided Pre-NDA Type B meeting minutes supporting the company’s NDA submission timeline.
- companyChiesi
Former collaboration partner; made a one-time $5M settlement and retained capped royalties/milestones after rights reacquisition by Gossamer.
